Observational studyCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Safety and Device Success of Transcatheter Aortic Valve Replacement: A 12-Year Single-Center VARC-3 Report.
Observational study in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) has become an established therapy for severe aortic stenosis (AS) across all surgical risk categories. However, data from Latin America remain scarce, particularly using standardized outcome definitions such as those from the Valve Academic Research Consortium-3 (VARC-3).
aimsTo describe baseline characteristics, technical and device success, and early clinical outcomes over a 12-year period at a single established TAVR program in Colombia.
methodsWe conducted a retrospective observational case series of consecutive patients with severe symptomatic AS who underwent TAVR between January 2012 and December 2023. Data were collected from institutional databases and electronic health records. Outcomes were defined according to VARC-3 criteria and assessed at 30 days. Procedural success and secondary endpoints were analyzed using the Wilson score method for 95% confidence intervals to account for the sample size. Exploratory temporal trend and multivariable logistic regression analyses were performed.
resultsA total of 134 patients were included (median age 80 years; 52.2% female). Technical success was achieved in 95.5%, and device success at 30 days in 81.3%. Thirty-day mortality was 7.4%; acute kidney injury (19.4%), permanent pacemaker implantation (18.7%), and vascular complications (12.7%) were the most common adverse events. In an exploratory multivariable model, diabetes mellitus was associated with increased 30-day mortality (AOR 1.25, 95% CI 1.07-2.41; p = 0.021), although this finding is limited by the low absolute number of events and should be interpreted with caution.
conclusionsIn this 12-year single-center experience, TAVR demonstrated high technical and device success with complication rates comparable to international benchmarks. These findings support the feasibility and safety of TAVR in a Latin American setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.